<DOC>
	<DOCNO>NCT01571232</DOCNO>
	<brief_summary>The purpose study test efficacy 0.7 mg intravitreal dexamethasone implant ( Ozurdex® ) macular leakage visual acuity patient recalcitrant diabetic macular edema .</brief_summary>
	<brief_title>Ozurdex Treatment Recalcitrant Diabetic Macular Edema</brief_title>
	<detailed_description>This open-label , Phase II comparative study intravitreal dexamethasone implant versus intravitreal bevacizumab ( Avastin ) 20 patient recalcitrant diabetic macular edema prior treatment ≥ 2 intravitreal anti-VEGF injection .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Presence NPDR PDR confirm fluorescein angiography Prior treatment &gt; = 2 intravitreal antiVEGF injection treatment last 4 week &lt; 0.1 LogOCT decrease macular edema high resolution OCT initial visit follow treatment &gt; = 2 intravitreal antiVEGF injection Age 18 year old ETDRS Visual acuity 3 78 letter ( approximate Snellen equivalent 20/25 20/800 ) Ability provide write informed consent Capable comply study protocol . Intraocular injection steroid medication within prior 3 month Evidence significant geographic atrophy fluorescein angiography opinion treat physician Concurrent ocular disease ( wet AMD , significant ERM , etc ) would limit visual acuity opinion treat physician Prior vitrectomy surgery Use systemic steroid ( eg , oral , intravenous , intramuscular , epidural , rectal , extensive dermal ) within 1 month prior day 1 . Known history IOP elevation response steroid treatment either eye result following : ) = 10 mm Hg increase IOP response steroid injection , b ) IOP = 25 mm Hg require 2 antiglaucoma medication keep IOP 21 mm Hg . Patients pregnant . Unwilling unable follow comply study relate procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Macular Edema</keyword>
	<keyword>DME</keyword>
	<keyword>PDR</keyword>
	<keyword>NPDR</keyword>
	<keyword>Ozurdex</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>